Recently added
This page was added on 27 June 2024.
Updates made
This page was updated on [date-counter-updated-date]. View history of updates
Sponsor
Pfizer Australia
Administration route
Intramuscular injection
Vaccine group
Adults aged ≥60 years and pregnant women for protection of their infant
Description:
Registered for use in:
- Pregnant women between 24–36 weeks of gestation
- Individuals ≥60 years
Recombinant Respiratory Syncytial Virus pre-fusion F protein vaccine (RSVPreF)
Powder and diluent for solution for injection
Each 0.5ml reconstituted dose contains:
- RSV subgroup A stabilised prefusion F protein 60 µg
- RSV subgroup B stabilised prefusion F protein 60 µg
- tromethamine
- tromethamine hydrochloride
- sucrose
- mannitol
- polysorbate 80
- sodium chloride
Also contains traces of
- hydrochloric acid
For Product Information and Consumer Medicine Information about Abrysvo visit the Therapeutic Goods Administration website.
Additional vaccine information
For detailed advice on vaccine dosage, administration, contraindications and precautions, and variations from product information, please visit the relevant disease chapter/s.
Page history
Last updated
Last reviewed
Related diseases